It is well established that a complex chromosomal karyotype is an adverse prognostic factor for MDS, and the absence of TP53 mutations in patients with complex karyotypes is associated with much better survival than that in patients with TP53 mutations (37). Here, TP53 is linked to myelodysplastic syndrome.